The use of tofacitinib in the treatment of inflammatory bowel disease
Насонов Е. Л., Абдулганиева Д. И., Фаирушина И. Ф.
Терапевтический архив
Т. 91, Вып. 2, С. 101-108
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.26442/00403660.2019.02.000155
Аннотация:
Major advances in pharmacology of the 21 st century include the development of a new class of drugs, which are low-molecular, chemically synthesized molecules (the so-called "small molecules"), the point of application of which is Janus kinase (Janus kinase, JAK) involved in intracellular cytokine signaling. The review examines the molecular aspects of the JAK-STAT signaling pathway, justifying the use of the JAK-kinase inhibitor (tofacitinib) in the treatment of inflammatory bowel disease. © 2019 Consilium Medikum. All rights reserved.
Ключевые слова:
Crohn's disease; Inflammatory bowel disease; JAK inhibitors; Tofacitinib; Ulcerative colitis
piperidine derivative; protein kinase inhibitor; pyrimidine derivative; pyrrole derivative; STAT protein; tofacitinib; drug effect; human; immunology; inflammatory bowel disease; metabolism; signal transduction; Humans; Inflammatory Bowel Diseases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors
Язык текста: Русский
ISSN: 2309-5342
Насонов Е. Л. Евгений Львович 1948-
Абдулганиева Д. И.
Фаирушина И. Ф.
Nasonov E. L. Evgenij L`vovich 1948-
Abdulganieva D. I.
Fairushina I. F.
The use of tofacitinib in the treatment of inflammatory bowel disease
Текст визуальный непосредственный
Терапевтический архив
Медицинское маркетинговое агентство "МедиаМедика"
Т. 91, Вып. 2 С. 101-108
2019
Статья
Crohn's disease Inflammatory bowel disease JAK inhibitors Tofacitinib Ulcerative colitis
piperidine derivative protein kinase inhibitor pyrimidine derivative pyrrole derivative STAT protein tofacitinib drug effect human immunology inflammatory bowel disease metabolism signal transduction Humans Inflammatory Bowel Diseases Piperidines Protein Kinase Inhibitors Pyrimidines Pyrroles Signal Transduction STAT Transcription Factors
Major advances in pharmacology of the 21 st century include the development of a new class of drugs, which are low-molecular, chemically synthesized molecules (the so-called "small molecules"), the point of application of which is Janus kinase (Janus kinase, JAK) involved in intracellular cytokine signaling. The review examines the molecular aspects of the JAK-STAT signaling pathway, justifying the use of the JAK-kinase inhibitor (tofacitinib) in the treatment of inflammatory bowel disease. © 2019 Consilium Medikum. All rights reserved.